Get the Stockscreener App
3.82
0.26%
0.010
After Hours:
3.84
0.02
+0.52%
Adagene Inc Adr stock is traded at $3.82, with a volume of 362.24K.
It is up +0.26% in the last 24 hours and down -7.51% over the past month.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
See More
Previous Close:
$3.81
Open:
$3.8
24h Volume:
362.24K
Relative Volume:
1.45
Market Cap:
$252.40M
Revenue:
$7.69M
Net Income/Loss:
$-17.65M
P/E Ratio:
-10.21
EPS:
-0.3743
Net Cash Flow:
$-15.72M
1W Performance:
-4.50%
1M Performance:
-7.51%
6M Performance:
+113.41%
1Y Performance:
+138.75%
1-Day Range:
$3.80
$3.955
1-Week Range:
$3.53
$4.0498
52-Week Range:
$1.30
$4.75
Adagene Inc Adr Stock (ADAG) Company Profile
Compare ADAG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
3.82 | 251.74M | 7.69M | -17.65M | -15.72M | -0.3743 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Guggenheim | Buy |
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Jan-31-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-25-21 | Initiated | China Renaissance | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Adagene Inc Adr Stock (ADAG) Latest News
Adagene appoints Peter Lebowitz to advisory board - Investing.com
Adagene appoints Peter Lebowitz to advisory board By Investing.com - Investing.com India
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - Bitget
H.C. Wainwright reiterates Adagene stock rating on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Adagene stock rating on trial data - Investing.com
Guggenheim Issues Positive Forecast for Adagene (NASDAQ:ADAG) Stock Price - MarketBeat
Guggenheim raises Adagene stock price target on cancer drug data - Investing.com
Guggenheim raises Adagene stock price target on cancer drug data By Investing.com - Investing.com South Africa
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs - Sahm
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Sahm
Leerink raises Adagene stock price target to $8 on combination data - Investing.com India
[424B5] Adagene Inc. Prospectus Supplement (Debt Securities) - stocktitan.net
Leerink raises Adagene stock price target to $8 on combination data By Investing.com - Investing.com South Africa
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update - wahanariau.com
Adagene sets $3.75 per ADS price for $70M offering - MSN
Adagene prices $70 million public offering at $3.75 per ADS By Investing.com - Investing.com India
Adagene Posts Strong Muzastotug Data and Incyte Collaboration in MSS Colorectal Cancer - TipRanks
Adagene prices $70 million public offering at $3.75 per ADS - Investing.com
Adagene Prices US$70 Million ADS Offering to Bolster Cancer Immunotherapy Pipeline - TipRanks
Adagene reports 31% response rate in colorectal cancer trial By Investing.com - Investing.com India
Adagene reports 31% response rate in colorectal cancer trial - investing.com
Adagene (Nasdaq: ADAG) prices $70M ADS sale at 30-day VWAP - Stock Titan
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Bitget
Adagene (ADAG) launches ADS offering to fund ADG126 and pipeline - Stock Titan
Updated Data from Phase 1b/2 Study of Muzastotug in - GlobeNewswire
Adagene (ADAG) reports stronger 20 mg/kg muzastotug results and Fast Track status - Stock Titan
Why Is ADAG Stock Tanking Today? - Stocktwits
Adagene (NASDAQ:ADAG) Announces Earnings Results, Beats Expectations By $0.24 EPS - MarketBeat
Adagene Posts 2025 Results as Muzastotug Data, Partnerships Extend Cash Runway to 2028 - TipRanks
Adagene (NASDAQ: ADAG) revenue jumps in 2025 as losses narrow and cash runway extends - Stock Titan
Regulatory pressure around China puts Adagene (ADAG) Nasdaq listing at risk - Stock Titan
Empowering Investor Success - Morningstar
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Expands By 44.6% - MarketBeat
ETFs Investing in Adagene, Inc. Sponsored ADR Stocks - tradingview.com
ADAG Stock Price, Quote & Chart | ADAGENE INC-ADR (NASDAQ:ADAG) - ChartMill
AirBoss of America (OTCMKTS:ABSSF) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
Alibaba Group (NYSE:BABA) Stock Price Down 2% on Analyst Downgrade - Defense World
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Adagene (NASDAQ:ADAG) Raised to Hold at Wall Street Zen - MarketBeat
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - wahanariau.com
Adagene Inc. (NASDAQ: ADAG) insider reports 2.39M shares, 5.1% stake - Stock Titan
Adagene (NASDAQ: ADAG) CSO reports options and warrant stakes - Stock Titan
Adagene (ADAG) CFO Tam Man Kin details shares, RSUs and options - Stock Titan
Adagene Inc. (ADAG) CEO Peter Luo reports options, RSUs and shares in Form 3 - Stock Titan
Adagene (ADAG) HR executive Form 3 details options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details stock option holdings - Stock Titan
Adagene (ADAG) finance leader lists options, RSUs and shares - Stock Titan
Adagene (NASDAQ: ADAG) director details 70,000-share option position in Form 3 - Stock Titan
Adagene (NASDAQ: ADAG) CMO discloses stock options, RSUs and shares - Stock Titan
Adagene Inc. (ADAG) director lists time and performance stock options - Stock Titan
Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA - Bitget
Adagene Inc Adr Stock (ADAG) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):